Gilteritinib received approval for patients with R/R FLT3-mutated AML based on the results of the ADMIRAL trial [147], which included 371 patients randomized to receive this agent alone (247 patients) or salvage ICT (124 patients). This evidence concerns the gene FLT3 and acute myeloid leukemia.